New Experimental Drug Could Stop Memory Loss

In Alzheimer's disease sufferers, a new class of drugs has proved to be effective in preventing early memory loss, finds research.

The small molecules, called MW108, stopped loss of memory and fixed damaged communication among brain cells in a mouse model of Alzheimer.

Alzheimer’s disease - Causes, Symptoms, Diagnosis, Stages, Types, Prevention, Prognosis & Treatment
Alzheimer's disease is a progressive neurodegenerative disease affecting memory and thinking and making the person increasingly dependent on others.

D. Martin Watterson, lead author of a paper on the study and the John G. Searle Professor of Molecular Biology and Biochemistry at Northwestern University Feinberg School of Medicine said that it is possible that someday this class of drugs could be given early on to people to arrest certain aspects of Alzheimer's.

Linda Van Eldik, a senior author of the paper and director of the University of Kentucky Sanders-Brown Center on Aging, said that these drugs can be beneficial when the nerve cells are just beginning to get damaged.

The novel drug-like molecule reduced activity of an enzyme that is over-activated during Alzheimer's and is considered a contributor to brain inflammation and impaired neuron function.

Quiz On Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common form of dementia. Participate in this quiz to find out how much you know about this debilitating disease.

Strong communication between neurons in the brain is an essential process for memory formation.

The compound strikes at a new, single target that has long flown under the radar in Alzheimer 's drug development. The target is a stress-related protein kinase, p38alpha MAPK.

Caring for Alzheimers disease patients
Alzheimer's disease is a complex brain disorder that triggers the most common form of dementia. The slide show will show how patients need support and care as dementia progresses.

Watterson said that they believe that the protein kinase target is one of the key players in the early to mid-stage of several diseases of the central nervous system and cancer.

In a key memory experiment in the study, mice brains were injected with beta-amyloid, whose increase is one hallmark of Alzheimer's in humans. One group of mice was then administered MW108 and another group was administered a placebo.

Protein That Contributes to Cognitive Decline in Alzheimer's Identified
Caspase-2 - a key regulator of a signaling pathway that leads to cognitive decline in Alzheimer's disease has been discovered by Columbia University Medical Center scientists.

Next, each group of mice was taught environmental cues to learn how to swim through a water maze to find a resting platform. Then the mice were placed in a different arm of the maze and tested on their ability to remember the location of the platform based on the environmental cues.

The mice administered MW108 found the resting platform in the water maze as quickly as a control group of mice. The mice given the placebo made more mistakes and took longer to find the platform. They also had difficulty learning the location of the resting platform during the teaching phase.

Van Eldik said that the results show the compound prevented the cognitive impairment.

The study has been published in the journal PLOS ONE.

Source-ANI